S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NYSE:PRLBProto Labs Stock Price, Forecast & News

$132.07
-0.34 (-0.26 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$131.00
Now: $132.07
$133.10
50-Day Range
$107.54
MA: $119.77
$137.93
52-Week Range
$63.19
Now: $132.07
$138.20
Volume142,302 shs
Average Volume282,604 shs
Market Capitalization$3.53 billion
P/E Ratio60.86
Dividend YieldN/A
Beta1.73
Proto Labs, Inc., together with its subsidiaries, operates as an e-commerce driven digital manufacturer of custom parts for prototyping and short-run production worldwide. It utilizes injection molding, computer numerical control machining, three-dimensional (3D) printing, and sheet metal fabrication to manufacture custom parts for developers and engineers who use 3D computer-aided design software to design products across a range of end markets. The company was founded in 1999 and is headquartered in Maple Plain, Minnesota.
Read More
Proto Labs logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.02 out of 5 stars


Industry, Sector and Symbol

Industry Fabricated structural metal products
Sub-IndustryIndustrial Machinery
CUSIP74371310
Phone763-479-3680

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$458.73 million
Cash Flow$3.58 per share
Book Value$21.89 per share

Profitability

Net Income$63.65 million

Miscellaneous

Employees2,535
Market Cap$3.53 billion
Next Earnings Date10/22/2020 (Estimated)
OptionableOptionable
$132.07
-0.34 (-0.26 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRLB News and Ratings via Email

Sign-up to receive the latest news and ratings for PRLB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Proto Labs (NYSE:PRLB) Frequently Asked Questions

How has Proto Labs' stock price been impacted by Coronavirus?

Proto Labs' stock was trading at $78.36 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRLB stock has increased by 68.5% and is now trading at $132.07.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Proto Labs?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proto Labs in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Proto Labs
.

When is Proto Labs' next earnings date?

Proto Labs is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020.
View our earnings forecast for Proto Labs
.

How were Proto Labs' earnings last quarter?

Proto Labs Inc (NYSE:PRLB) posted its quarterly earnings results on Tuesday, July, 28th. The industrial products company reported $0.59 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.36 by $0.23. The industrial products company earned $106.60 million during the quarter, compared to the consensus estimate of $100.46 million. Proto Labs had a net margin of 12.99% and a return on equity of 10.02%. The firm's quarterly revenue was down 8.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.71 earnings per share.
View Proto Labs' earnings history
.

What price target have analysts set for PRLB?

6 brokers have issued twelve-month price objectives for Proto Labs' shares. Their forecasts range from $69.00 to $145.00. On average, they anticipate Proto Labs' stock price to reach $98.00 in the next twelve months. This suggests that the stock has a possible downside of 25.8%.
View analysts' price targets for Proto Labs
.

Has Proto Labs been receiving favorable news coverage?

News stories about PRLB stock have trended somewhat negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Proto Labs earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave headlines about the industrial products company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
View the latest news about Proto Labs
.

Who are some of Proto Labs' key competitors?

What other stocks do shareholders of Proto Labs own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Proto Labs investors own include NVIDIA (NVDA), Tesla (TSLA), Brainstorm Cell Therapeutics (BCLI), Netflix (NFLX), Walt Disney (DIS), Cisco Systems (CSCO), Gilead Sciences (GILD), Starbucks (SBUX), Advanced Micro Devices (AMD) and Activision Blizzard (ATVI).

Who are Proto Labs' key executives?

Proto Labs' management team includes the following people:
  • Ms. Victoria M. Holt, Pres, CEO & Director (Age 61)
  • Mr. John A. Way, CFO & Exec. VP of Devel. (Age 46)
  • Dr. Arthur Richard Baker III, Chief Technology Officer (Age 51)
  • Mr. David M. Fein, Chief Revenue Officer (Age 50)
  • Dan Schumacher, Director of Investor Relations and FP&A

What is Proto Labs' stock symbol?

Proto Labs trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRLB."

Who are Proto Labs' major shareholders?

Proto Labs' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.12%), Riverbridge Partners LLC (5.73%), Sumitomo Mitsui Trust Holdings Inc. (4.91%), New York State Common Retirement Fund (1.94%), Conestoga Capital Advisors LLC (1.68%) and Bank of New York Mellon Corp (1.24%). Company insiders that own Proto Labs stock include Arthur R Baker III, John B Goodman, John Way, Robert Bodor and Sven Wehrwein.
View institutional ownership trends for Proto Labs
.

Which major investors are selling Proto Labs stock?

PRLB stock was sold by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, Conestoga Capital Advisors LLC, Goldman Sachs Group Inc., Vanguard Group Inc., Summit Creek Advisors LLC, Mairs & Power Inc., Man Group plc, and SG Americas Securities LLC. Company insiders that have sold Proto Labs company stock in the last year include Robert Bodor, and Sven Wehrwein.
View insider buying and selling activity for Proto Labs
.

Which major investors are buying Proto Labs stock?

PRLB stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Premier Asset Management LLC, Nicholas Investment Partners LP, Riverbridge Partners LLC, EAM Investors LLC, Cubist Systematic Strategies LLC, Balyasny Asset Management LLC, and Bank of New York Mellon Corp.
View insider buying and selling activity for Proto Labs
.

How do I buy shares of Proto Labs?

Shares of PRLB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Proto Labs' stock price today?

One share of PRLB stock can currently be purchased for approximately $132.07.

How big of a company is Proto Labs?

Proto Labs has a market capitalization of $3.53 billion and generates $458.73 million in revenue each year. The industrial products company earns $63.65 million in net income (profit) each year or $2.35 on an earnings per share basis. Proto Labs employs 2,535 workers across the globe.

What is Proto Labs' official website?

The official website for Proto Labs is www.protolabs.com.

How can I contact Proto Labs?

Proto Labs' mailing address is 5540 Pioneer Creek Drive, Maple Plain MN, 55359. The industrial products company can be reached via phone at 763-479-3680 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.